Berrada S, Mahdi L, El Hassani M, Kouach J and Moussaoui D
Clear cell carcinomas (CCCs) occur most often in young women (median age: 20 years) even before the first pregnancy. It is essential to be conservative and to respect the genital system as much as possible to preserve ovarian hormonal function and fertility. Mutations in KRAS, BRAF, and TP53 are present in some clear cell carcinomas, but their frequency is generally low. Mutations predicted to deregulate PI3K/PTEN signaling. Because of resistance to the usual platinum and taxane chemotherapies, the advanced stages have a much worse prognosis than that of serous tumors. Thus, some studies have suggested that CCCs may be more sensitive to a combination of irinotecan than paclitaxel-based chemotherapy.
PDFShare this article
Cancer Science & Therapy received 3968 citations as per Google Scholar report
